Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha (Q44221454)
Jump to navigation
Jump to search
scientific article published on 15 October 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha |
scientific article published on 15 October 2002 |
Statements
1 reference
Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha (English)
1 reference
Andries Bloem
1 reference
Gerard Groenewegen
1 reference
Gijsbert C De Gast
1 reference
15 October 2002
1 reference
1 reference
51
1 reference
11-12
1 reference
630-636
1 reference
Identifiers
1 reference
1 reference